|

Oncolytic Adenovirus Ad5-DNX-2401 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Ad5-Delta24RGD, DNX-2401, DNX2401, Oncolytic Ad5-Delta 24RGD, Oncolytic Adenovirus Ad5-Delta 24RGD

Pipeline

Phase 1: 1

Top Sponsors

  • M.D. Anderson Cancer Center1

Indications

  • Recurrent Anaplastic Astrocytoma1
  • IDH1 wt Allele1
  • Recurrent Malignant Glioma1
  • Recurrent Gliosarcoma1
  • Recurrent Glioblastoma1

Houston, Texas1 trial

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.